Liangjie Ma

Liangjie Ma

Auto-generated profile, based on publicly available information

Liangjie Ma

Graduate School, Beijing University of Chinese Medicine, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Digital Health
Verified
Journal Article
Open access
YWYi-Fei Wang
Yi-Fei Wang
LMLiang-Jie Ma
Liang-Jie Ma
YHYu-Xin Han
Yu-Xin Han
GCguangyao chen
guangyao chen
XMXiao Ma
Xiao Ma
Objective: To systematically explore international research trends and dynamics in the interdisciplinary field of artificial intelligence (AI) and pain management over the past decade (2016-2025) and delineate current research frontiers. Methods: Publications were retrieved from Web of Science Core Collection database and subjected to bibliometric analysis. VOSviewer, Scimago Graphica, and other tools were used for bibliometric analysis and visualization. Results: A total of 1022 articles were included. Publication output showed an exponential upward trend overall, despite a temporary slowdown in 2022, followed by accelerated growth from 2023 onward. The United States led in global publication volume and served as the core hub of international collaborative networks, followed by China. In terms of journals, Pain published the highest number of relevant studies. Regarding authorship, Cao Rui, Wang Bin, and David Borsook emerged as the most influential scholars. Reference and keyword analyses delineate a clear evolution: early research established foundational insights into mechanisms. Mid-period work integrated AI and machine learning with multimodal tools like functional magnetic resonance imaging (fMRI) for objective assessment; recent advances have shifted toward clinical translation, focusing on precision medicine and the refinement of pain classification and assessment frameworks. Conclusion: This study maps the evolutionary trajectory of AI research in pain management over the past decade. Future efforts should prioritize strengthening international collaboration, promoting large-scale clinical validation of AI tools, standardizing data sharing, and addressing equity in access to technology to meet unmet clinical needs in pain care.

1 August 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YHYuxin Han
Yuxin Han
PWPengrui Wang
Pengrui Wang
YWYifei Wang
Yifei Wang
GCguangyao chen
guangyao chen
MLMeiqi Lan
Meiqi Lan
YZYanzhen Zhang
Yanzhen Zhang
Objective: Rheumatoid arthritis (RA) is a chronic autoimmune joint disease driven by dysregulated immune cells and transcription factors. Despite known molecular alterations, systematic screening of key biomarkers and their link to the immune microenvironment remains lacking, particularly regarding extensive multi-algorithm cross-validation across multiple independent cohorts. This study employs bioinformatics and machine learning to identify potential RA biomarkers, aiming to support diagnosis and targeted therapy. Methods: Multiple RA-related transcriptomic datasets derived from synovial tissue were integrated from the GEO database to screen differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) was performed to identify RA-associated modules. A total of 107 parameter and algorithm permutations from 11 distinct machine learning approaches were employed to screen key feature genes. The optimal model was selected based on average AUC values across training and validation sets, and the final three genes were identified by integrating individual diagnostic performance, biological relevance, and experimental validation. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves, while decision curve analysis (DCA) and confusion matrices were applied to validate the clinical net benefit and classification performance of the model. Immune infiltration analysis was used to assess alterations in immune cell composition within the RA microenvironment. Collagen-induced arthritis (CIA) was used to establish rat models of RA in Sprague-Dawley (SD) rats with a modest sample size (control n = 4, CIA n = 6). Ankle joint tissues were harvested for pathological examination, and the key targets were further validated by immunohistochemistry, serving as a preliminary biological corroboration of the computational findings. Results: Through differential expression analysis and WGCNA, a set of RA-related candidate genes was identified. After combined screening using 107 parameter and algorithm permutations and ROC curve evaluation, FOSL2, JUN, and EGR1 were ultimately determined as potential biomarkers for RA. These genes demonstrated good individual diagnostic accuracy (AUC > 0.8). Immune infiltration analysis consistently revealed significant enrichment of mast cells in the RA microenvironment. The CIA model rats were successfully established, and immunohistochemistry results showed significantly high expression of FOSL2, JUN, and EGR1 in the synovial tissue. Conclusion: This study identifies FOSL2, JUN, and EGR1 as potential markers for RA, supporting their potential roles in RA pathogenesis and clinical application.

1 August 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YWYifei Wang
Yifei Wang
YHYuxin Han
Yuxin Han
FTFei Teng
Fei Teng
YLYi Liu
Yi Liu
LMLiangjie Ma
Liangjie Ma
XMXiao Ma
Xiao Ma
Objective: The total glucosides of paeony (TGP), extracted from the roots of Paeonia lactiflora Pall., represent its primary bioactive fraction. Emerging evidence supports its clinical potential in treating ulcerative colitis (UC). Nevertheless, a systematic understanding of its underlying pharmacological mechanisms remains insufficient. This study aims to comprehensively investigate the multi-target, multi-pathway therapeutic mechanisms of TGP against UC by employing an integrated strategy combining network pharmacology and untargeted metabolomics, with subsequent experimental validation. Methods: Induction of the colitis mouse model was performed by supplementing drinking water with dextran sulfate sodium (DSS), and an in vitro model was created by treating NCM460 intestinal epithelial cells with lipopolysaccharide. The DSS-induced colitis mice were orally administered low-, medium-, or high-dose TGP at 0.093, 0.185, or 0.369 g/kg/day, respectively, while LPS-stimulated NCM460 cells were treated with TGP at 100, 200, or 400 μg/mL. The therapeutic effects of TGP were assessed in vivo through the disease activity index (DAI), colon length measurement, and histopathological examination. Colon tissues were collected for subsequent non-targeted metabolomics analysis via liquid chromatography- tandem mass spectrometry (LC-MS/MS). The mechanisms underlying the effects of TGP were explored through integrated network pharmacology and metabolomics studies and further verified using RT-PCR, ELISA, Western blot, and flow cytometry. Results: TGP treatment significantly decreased DAI scores, reduced colon shortening, and ameliorated histopathological lesions in the DSS-induced colitis mouse model. Network pharmacology analysis revealed that the therapeutic effects of TGP on UC are primarily mediated through various inflammatory mediators and signaling pathways. Integrated metabolomics analysis further identified the COX-2-mediated arachidonic acid pathway as a key pathway. Both in vivo and in vitro, TGP dose-dependently reduced the expression of IL-6, TNF-α, and COX-2 and suppressed the activation of AKT, p38 MAPK, and NF-κB signaling. In DSS-treated mice, TGP-H reduced the splenic Th17/Treg ratio. Conclusion: TGP exerts its therapeutic effects on UC through the inhibition of various inflammatory targets and signaling pathways.